Accelerate biotechnology

$2.2 million follow-up grant from PATH to support new tools for polio eradication era

Leiden, 4 Jul 2019 – Today, Batavia Biosciences announces it received a follow-up grant of $2.2 million from PATH – a global organization dedicated to health equity – to develop and manufacture novel oral poliovirus vaccines (nOPV). The project, which is funded by the Bill & Melinda Gates Foundation, aims to protect children worldwide from…


$14.3M grant to deliver affordable measles & rubella vaccines

BRUSSELS, BELGIUM – JUNE, 13 2019 Univercells announced today that it has been awarded a $14.3 million grant by the Bill & Melinda Gates Foundation to increase the availability of measles and rubella (M&R) vaccines in low- and middle-income countries (LMICs). Univercells will adapt the process design of its proprietary NevoLine™ platform to deliver affordable M&R…


Next-geneneration gene therapy for patients with heart disease

The European Union has awarded €15 million to the CardioReGenix consortium, as part of the Horizon2020 program. The research program is initiated to develop new gene therapy approaches for the treatment of heart disease. The program is coordinated by Professor Marinee Chuah from the Free University of Brussels (VUB) and includes thirteen international partners, including…


Batavia Biosciences receives $13.2M grant to accelerate market access of low-cost inactivated polio vaccine

Leiden, The Netherlands, February 25, 2019 – Batavia Biosciences announced today that it received a $13.2 million grant from the Bill & Melinda Gates Foundation to manufacture clinical-grade inactivated polio vaccine (sIPV), using its newly developed low-cost polio vaccine manufacturing process (marketed as HIP-IPVTM) based on the NevoLine™ manufacturing technology developed by Univercells. In 2016,…


Introduction breakthrough vaccine manufacturing platform

Univercells, a business-to-business provider focused on increasing the availability of affordable biologics to address global health challenges, announced today the commercial launch of its proprietary NevoLine™ bioproduction system for vaccines. The system was initially developed as part of a $12M Grand Challenges grant awarded by the Bill & Melinda Gates Foundation to deliver affordable inactivated polio vaccine (sIPV). Leading…


Batavia Biosciences partners with IAVI to advance development of vaccine against Lassa fever

Leiden, December 11, 2018 – Batavia Biosciences announces today that the International AIDS Vaccine Initiative (IAVI) and Batavia Biosciences will work together under a grant to advance the development of a Lassa fever vaccine. With this grant, Batavia Biosciences will leverage its novel, highly intensified manufacturing technology to develop a low-cost, easy-to-implement manufacturing process. This…


Batavia Biosciences wins FD Gazelle Award for 4th consecutive year

We are proud to announce that Batavia Biosciences has again been awarded with an FD Gazelle Award 2018 by the leading Dutch financial newspaper, Financieel Dagblad as one of the fastest growing mid-sized companies of the Netherlands. It is the fourth time we have won an FD Gazelle Award and we hope that many more…


Batavia Biosciences is Best Biopharmaceutical CDMO 2018

Today, GHP Announces Winners of the Healthcare & Pharmaceutical Awards 2018. We are very proud to announce that Batavia Biosciences has been awarded “Best Biopharmaceutical Contract Development & Manufacturing Company 2018”. According to GHP: “The awards are given solely on merit and were awarded to commend those most deserving for their ingenuity and hard work, distinguishing…


CEO OF THE YEAR, 2018 title awarded to Batavia Biosciences!

We are pleased to announce that Dr. Menzo Havenga has been awarded the title CEO OF THE YEAR 2018- CONTRACT DEVELOPMENT AND MANUFACTURING. The European CEO Awards organization celebrates global business leaders that are making major strides in their respective fields. The organization recognizes product, service, functional, strategic, and managerial innovation in companies and individuals showing commercial insight and market integrity….